HomeNewsBusinessEmerging markets face wave of unrest as lockdowns ease, finds risk study
Trending Topics

Emerging markets face wave of unrest as lockdowns ease, finds risk study

Thirty-seven countries are at risk, mostly concentrated in Africa and Latin America, including Nigeria, Democratic Republic of Congo, Ethiopia, Venezuela and Peru

July 17, 2020 / 07:50 IST
Story continues below Advertisement
Representative Image (Source: Reuters)
Representative Image (Source: Reuters)

Dozens of emerging and frontier markets are likely to face mass protests in the coming months as lockdowns imposed to control the coronavirus pandemic ease and the dire economic impact of the virus hits home, according to new research.

Thirty-seven countries are at risk, mostly concentrated in Africa and Latin America, including Nigeria, Democratic Republic of Congo, Ethiopia, Venezuela and Peru, said global risk analysis company Verisk Maplecroft.

Story continues below Advertisement

Congo and Ethiopia, as well as Belarus, Bulgaria and Serbia in Europe, are among countries to have been shaken by protests in recent days as dissatisfaction with governments boils over.

This follows a drop in unrest in emerging and frontier markets in March, according to Armed Conflict Location & Event Data (ACLED), after the widespread introduction of lockdowns.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show